DRTS

Alpha Tau Medical

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 1

consensus rating "Strong Buy"

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About DRTS

Alpha Tau Medical Ltd.

A developer of alpha radiation cancer therapy designed to treat solid tumors

Industry

Life Science Tools and Services

Established Date

Invalid Date

Listing Date

03/08/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

125

Fiscal Year Ends

12-31

Website

www.alphatau.com

Security Type

Common stock

Office address

Kiryat HaMada St. 5, Jerusalem 9777605, Israel

Business

Introduction

Alpha Tau Medical Ltd., a company established in Israel in 2016. The Company is a clinical-stage oncology company focused on local radiotherapy for solid tumors utilizing innate relative bioavailability and short-course α granules. The company's proprietary Alpha DaRT technology is designed to take advantage of the specific therapeutic properties of alpha particles, while aiming to overcome or even exploit the traditional disadvantages of limited range of alpha radiation for potential benefits. The company has conducted several clinical trials in clinical sites around the world to evaluate and continue to evaluate the feasibility, safety and efficacy of Alpha DaRT technology in the treatment of superficial lesions, namely skin, head or neck tumors.

Company Financials

EPS

DRTS has released its 2024 Q4 earnings. EPS was reported at -0.14, versus the expected -0.13, missing expectations. The chart below visualizes how DRTS has performed over recent quarters, highlighting trends in earnings surprises.